Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 5/20 | 0.70 |
| ▸ | TOP2B | Q02880 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7567582 | 0.92 | TOP2A (0.73) | TOP2ATOP2B | |
| SCHEMBL7570128 | 0.91 | TOP2A (0.74) | TOP2ATOP2BMEN1KMT2A | |
| SCHEMBL3981533 | 0.91 | TOP2A (0.80) | TOP2ATOP2BMAPTMEN1KMT2A | |
| SCHEMBL7561273 | 0.89 | TOP2A (0.70) | TOP2ATOP2BMAPTNPC1RAB9A | |
| SCHEMBL7564523 | 0.87 | TOP2A (0.71) | TOP2ATOP2BMAPTMEN1KMT2A | |
| SCHEMBL7563590 | 0.86 | TOP2A (0.70) | TOP2ATOP2BMAPTKMT2ALMNA | |
| SCHEMBL7561275 | 0.86 | TOP2A (0.66) | TOP2ATOP2B | |
| SCHEMBL7564578 | 0.85 | TOP2A (0.71) | TOP2ATOP2B | |
| SCHEMBL7563689 | 0.85 | TOP2A (0.77) | TOP2ATOP2BMAPTKMT2ALMNA | |
| SCHEMBL7568574 | 0.84 | TOP2A (0.73) | TOP2ATOP2BMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020111491-A1 | 9-aminoacridine derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111491-A1 | 9-aminoacridine derivatives and process for the preparation thereof | ALKBH1, ADCY9, CCR9 | TOP2A 1105/4885TOP2B 841/4885MAPT 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.